On Aug. 7, 2024, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved CREXONT ^® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD).

CREXONT is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and extended-release (ER) pellets. Existing oral IR CD/LD products are short-acting, and patients can experience more motor fluctuations and less daily “Good On” time, defined as “On” time without troublesome dyskinesia, as the disease progresses.